Pharma companies focusing more on core areas'

Pharma |  Company results | By BioSpectrum Bureau  | 0 Comment | 05 May, 2014

Bangalore: On April 25, 2014, Biocon declared its FY14 performance results at its Bangalore campus, revealing 16 percent growth in its revenues, with revenues touching Rs 2,933 crore, follo...Read more

Biogen Idec multiple sclerosis drug gets FDA nod

Pharma |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 15 Apr, 2013

Singapore: Biogen Idec received approval for Tecfidera (dimethyl fumarate) as a new first-line oral treatment for people with relapsing forms of multiple sclerosis (MS) from the US FDA. Tec...Read more

Sanofi reports +ve results despite patent expirations

Pharma |  Company results | By BioSpectrum Bureau  | 0 Comment | 11 Feb, 2013

Singapore: Sanofi reported sales of $11.40 billion (€8,526 million), an increase of 0.2 percent, during the fourth quarter (Q4) of 2012. Exchange rate movements had a positive effect ...Read more

Pharma sector witnesses dip in hiring

Pharma |  News | By BioSpectrum Bureau  | 0 Comment | 13 Nov, 2012

New Delhi: The recruitment levels for the pharma sector in India witnessed a decrease of five percent in October 12, when compared to last month. This negative trend has been continuously h...Read more

Novartis appoints a new oncology president

Pharma |  News | By BioSpectrum Bureau  | 0 Comment | 02 Jun, 2014

Singapore: Swiss drug giant Novartis, announced on June 1, that it had appointed Mr Bruno Strigini as the president of its oncology division. Mr Stringini had earlier served Merck & Co....Read more

Prana Alzheimer's trial shows +ve results

Pharma |  News | By BioSpectrum Bureau  | 0 Comment | 08 Apr, 2013

Singapore: Prana Biotechnology reported on the progress of its lead development asset PBT2, which is in phase II trials for Huntington disease and Alzheimer's disease. Across the two trials...Read more

India may halt foreign investment in pharma

Pharma |  News | By BioSpectrum Bureau  | 0 Comment | 20 Sep, 2013

Singapore: As a resolution to the ongoing debate about whether to restrict foreign direct investment (FDI) in the existing pharmaceutical projects in India, the country's health ministry ha...Read more

Novartis posts 20 percent rise in Q1 profit

Pharma |  Company results | By BioSpectrum Bureau  | 0 Comment | 29 Apr, 2014

Singapore: Novartis announced that it has recorded a 20 percent rise in its first-quarter profit. Reports said that the net profit attributable to shareholders climbed to $2.94 billion fro...Read more

Study shows Lipitor well-tolerated among Asians

Pharma |  News | By BioSpectrum Bureau  | 0 Comment | 07 Nov, 2012

Singapore: A large-scale retrospective database analysis on atorvastatin (Lipitor) by Astellas Pharma and Pfizer Japan has demonstrated that atorvastatin is as well tolerated by the Asian p...Read more

Astellas to do interim analysis of cancer trial

Pharma |  News | By BioSpectrum Bureau  | 0 Comment | 03 Apr, 2013

Singapore: Medivation and Astellas Pharma have established an updated interim analysis plan for the Prevail trial, a global phase III clinical trial evaluating Xtandi (enzalutamide) capsule...Read more

Novartis acquires cancer firm CoStim

Pharma |  News | By BioSpectrum Bureau  | 0 Comment | 18 Feb, 2014

Singapore: Global pharmaceutical firm, Novartis, has acquired CoStim Pharmaceuticals, a privately held biotechnology company, broadening its cancer immunotherapy research program. Increasi...Read more

AIDS 2014 kicks off in Melbourne

Pharma |  News | By BioSpectrum Bureau  | 0 Comment | 21 Jul, 2014

Singapore: 20th International AIDS Conference (AIDS 2014), kicked off in Melbourne on July 20th, with a gathering of over 12,000 participants including global leaders, researchers, activist...Read more

EMA: Osteoporosis drug causes heart problems

Pharma |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 29 Apr, 2013

Singapore: The European Medicine Agency (EMA) recommended restriction in the use of the osteoporosis medicine Protelos/Osseor, following an assessment of data showing an increased risk of s...Read more

FDA re-inspects AMRI Burlington facility

Pharma |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 24 Jul, 2013

Singapore: FDA has issued warning letter to Albany Molecular Research (AMRI) in connection with an inspection of the company's pharmaceutical manufacturing facility located in Burlington, M...Read more

ShangPharma appoints committee chairman

Pharma |  News | By BioSpectrum Bureau  | 0 Comment | 18 Jul, 2012

Singapore: ShangPharma, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, has appointed Mr Yuk Lam Lo as the chairman of the independent c...Read more

Pharma industry sets eyes on $25 bn exports by 2014

Pharma |  News | By BioSpectrum Bureau  | 0 Comment | 02 Oct, 2012

Hyderabad: Innovation and government support are key to reach the $25 billion export target set by the India government for the pharmaceutical sector. Heads of major pharma companies, who g...Read more

Teva and Lonza terminate biosimilars joint venture

Pharma |  News | By BioSpectrum Bureau  | 0 Comment | 26 Jul, 2013

Singapore: Teva Pharmaceutical Industries and Lonza Group have conducted a strategic review of the Teva-Lonza Joint Venture (TL-JV) and have decided to discontinue their collaboration for ...Read more

GSK admits to fraud in the US, pays $3 bn in penalty

Pharma |  Analysis | By BioSpectrum Bureau  | 0 Comment | 05 Jul, 2012

Bangalore: British pharmaceutical giant GlaxoSmithKline (GSK), which was facing civil and criminal liabilities in the US for unlawful promotion of certain prescription drugs and failure to ...Read more